Exploring the relationship between DEPDC1 expression and TKIs for first-line treatment of advanced RCC using the Genomics of GDSC database demonstrated that the sensitivity to sunitinib and pazopanib was enhanced in the low DEPDC1 expression group, as evidenced by lower IC50 of response compared to the high-expression group (Fig. 2f, g). Here, DEPDC1 is linked to renal cell carcinoma.